We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.40 | -1.85% | 180.00 | 180.00 | 180.40 | 183.00 | 179.20 | 179.20 | 392,700 | 14:52:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 126.21M | 15.89M | 0.0732 | 25.00 | 397.5M |
From Apr 2019 to Apr 2024
TIDMAMS
RNS Number : 4807A
Advanced Medical Solutions Grp PLC
12 September 2018
12 September 2018
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Interim Results for the six months ended 30 June 2018
Winsford, UK, 12 September 2018: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces its unaudited interim results for the six months ended 30 June 2018.
Financial Highlights:
Hot Features
Premium
H1 2018 H1 2017 Reported Growth
growth at constant
currency(1)
Group revenue (GBP million) 47.6 46.1(6) 3% 6%
-------- -------- --------- -------------
Adjusted(5) profit before
tax (GBP million) 13.7 11.5 19% -
-------- -------- --------- -------------
Profit before tax (GBP million) 13.6 11.4 19% -
-------- -------- --------- -------------
Adjusted(2) diluted earnings
per share (pence) 5.01 4.31 16% -
-------- -------- --------- -------------
Diluted earnings per share
(pence) 4.99 4.26 17% -
-------- -------- --------- -------------
Net operating cash flow(3)
(GBP million) 13.7 9.1 51% -
-------- -------- --------- -------------
Net cash (GBP million)(4) 71.1 55.2 29% -
-------- -------- --------- -------------
Interim dividend per share
(pence) 0.42 0.35 20% -
-------- -------- --------- -------------
Business Highlights (including post-period end):
-- Group revenues up 3% to GBP47.6 million and by 6% at constant currency
o Strong growth in Branded, offset by slow-down in OEM
-- Gross margin improvement of 300 basis points to 63% (2017 H1: 60%)
-- Branded revenues up 10% to GBP30.1 million (2017 H1: GBP27.4 million(6) ) and by 12% at constant currency
-- Continued strong performance with LiquiBand(R) tissue adhesives
o US revenues up 16% to GBP10.5 million (2017 H1: GBP9.1 million), and by 27% at constant currency
o US market share volume increased to 28% (June 2017: 24%)
o LiquiBand(R) Fix8(TM) revenues up 16% at reported and constant currency to GBP1.0 million (2017 H1: GBP0.8 million) following the successful completion of recent design modifications
-- RESORBA(R) branded products, up 9% to GBP11.1 million (2017 H1: GBP10.2 million) and by 6% at constant currency
-- OEM revenues down 6% to GBP17.6 million (2017 H1: GBP18.7 million(6) ) and by 4% at constant currency
o Impacted by weakness in the woundcare market and by the decision of one partner to exit the market altogether
o Approval to market Surgical Silver Post-Operative dressings and PHMB Foam dressings in US received in August 2018 and launches planned for the fourth quarter
Commenting on the interim results, Chris Meredith, CEO of AMS, said:
"The Group has delivered another good set of results and is trading in line with Board expectations for the full year.
"We remain optimistic about the Group's organic growth prospects, with our R&D pipeline continuing to deliver products that strengthen our innovative portfolio. In addition, we are actively monitoring and evaluating acquisition opportunities to capitalise on our strong financial and strategic position."
- End -
Notes
1 Constant currency adjusts for the effect of currency movements by re-translating the current period's
performance at the previous period's exchange rates
2 All items are shown before amortisation of acquired intangible assets which, in 2018 H1, were less than GBP0.1 million (2017 H1: GBP0.1 million) as defined in the financial review
3 Operating cash flow is arrived at by taking the operating profit for the period and adjusting it for depreciation, amortisation, working capital movements and other non-cash items (see table 3)
4 Net cash is defined as cash and cash equivalents plus short term investments less financial liabilities and bank loans
5 Adjusted profit before tax is adjusted for exceptional items and amortisation of acquired intangible assets
6 2017 H1 Revenue increased by GBP0.2 million (Branded GBP0.1 million, OEM GBP0.1 million) as a result of adoption of IFRS 15 (Revenue from Contracts with Customers) in 2017, with these amounts being reclassified from Other Income to Revenue
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Mary Tavener, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Nicholas
Brown / Olivia Manser
Investec Bank plc (NOMAD) & Broker Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand(R) , RESORBA(R) , LiquiBand(R) Fix8(TM) and ActivHeal(R) as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.
Chairman's Statement
AMS continues to perform well and is well positioned to deliver another year of good growth and strong financial performance.
The Group's strategic initiatives continue to be to deliver growth by:
-- Innovation -- Geographic expansion -- Licencing and acquisition
Revenue increased by 3% to GBP47.6 million (2017 H1: GBP46.1 million(6) ) and by 6% at constant currency. Adjusted profit before tax(5) increased by 19% to GBP13.7 million (2017 H1: GBP11.5 million). Our net cash position(4) at 30 June 2018 was GBP71.1 million (31 December 2017: GBP62.5 million).
Good progress has been made with our surgical brands. LiquiBand(R) continues to gain market share in the US, now at 28%, gaining 4% since June 2017. Our RESORBA(R) brands grew steadily across all territories and LiquiBand(R) Fix8(TM) demonstrated strong growth following the completion of recent design modifications.
Our financial progress in OEM has been impacted by both a general slow-down in the woundcare market and by one of our US partners deciding to exit the market. Whilst this temporary setback is disappointing, we have multiple opportunities underway to drive future growth through market expansion and from the launch of new products later this year. These new products demonstrate the inherent value of our R&D and Regulatory capabilities which are a key pillar of our strategy to drive organic growth, supporting our OEM customers and end users.
Dividend
The Board intends to pay an interim dividend of 0.42p per share (2017 H1: 0.35p), an increase of 20%, on 26 October 2018 to shareholders on the register at the close of business on 29 September 2018.
Team
As announced at our AGM in June 2018, Mary Tavener intends to retire from the role of Chief Financial Officer and Board Director on 31 December 2018 after 19 years with the Company, and that Eddie Johnson, who has been with AMS for more than six years, and is currently the Group Financial Controller, will assume the role of Chief Financial Officer and join the Board. We would like to thank Mary for her 19 years of dedicated and outstanding service to AMS. In her time with the Group, she has been integral to our listing on AIM, several acquisitions and this has culminated in AMS growing for 13 consecutive years.
We are also pleased to announce that Alan Richardson will be joining the Group as Chief Operations Officer on 5 November 2018 from ConvaTec. He will assume responsibility for our Group Operations, Quality and Regulatory functions and brings with him a wealth of experience.
Mary will be working with both Eddie and Alan to ensure a smooth transition before her departure.
On behalf of the Board, I would like to thank all employees for their continued hard work that has helped AMS to prosper as a global medical technology business, as well as our customers, suppliers, business partners and shareholders for their continued support.
Summary
The Group continues to deliver good results and is trading in line with Board expectations for the year ending 31 December 2018.
Peter Allen
Chairman
Chief Executive's Review
I am pleased to report that the Group again performed well in the period.
Business Review
Branded Business Unit
Branded revenue increased by 10% to GBP30.1 million (2017 H1: GBP27.4 million(6) ) and by 12% at constant currency.
LiquiBand(R)
LiquiBand(R) , our range of cyanoacrylate based medical adhesives, is our largest brand with sales of GBP14.6 million (2017 H1: GBP13.0 million), an increase of 12% on prior year and a 19% increase at constant currency. It is sold in over 60 countries and includes different formulations and designs used to close wounds topically in the Operating Room and Accident and Emergency setting.
The US is our largest market and the Group continues to gain market share from the market leader. Our strategy in this market is to work with distributors that are able to target both hospitals and non-hospitals, helping to identify customers and convert opportunities into sales. Sales increased by 16% to GBP10.5 million (2017 H1: GBP9.1 million) and by 27% at constant currency with our portfolio of cyanoacrylate formulations successfully addressing the needs of the market. Our overall US market share by volume now stands at 28%, an increase of 4% since June 2017.
Sales of LiquiBand(R) in the UK and Germany reduced by 4% to GBP2.7 million (2017 H1: GBP2.8 million) and by 6% at constant currency. Sales through our distributors in other territories, increased by 20% to GBP1.4 million (2017 H1: GBP1.2 million) and 21% at constant currency.
In R&D, we are developing a device for closing large wounds for which we expect to receive approval to market in the US later this year. We also continue to work on extending our ranges of formulations for the base monomers used in our adhesives, with products expected to launch next year.
LiquiBand(R) Fix8(TM)
The design modifications for LiquiBand(R) Fix8(TM), our hernia mesh fixation device were completed in the first quarter of 2018, and the new version is now being fully promoted. Surgeon feedback has been extremely positive, and we recorded our highest level of quarterly sales for this product in Q2 2018 resulting in H1 2018 sales increasing by 16% at reported and constant currency to GBP1.0 million (2017 H1 GBP0.8 million). Clinical work is ongoing to broaden the claims to include other laparoscopic surgical applications, such as gastric sleeve surgery.
At present, the laparoscopic device is approved for use in Europe and those markets that accept European approval standards. We have begun the US approval process which is expected to take another two years and to cost approximately GBP3 million as it will necessitate a full set of clinical trials. These are expected to start early next year, once we obtain the Investigational Device Exemption with the FDA.
Development of the open surgery hernia mesh fixation device is close to completion and EU approval for this product is expected this year.
We continue to be excited for the long term prospects for LiquiBand(R) Fix8(TM).
RESORBA(R)
Our RESORBA(R) branded products portfolio is comprised of a comprehensive range of sutures and a range of bio-surgical products that include collagens and oxidised cellulose. Sales of RESORBA(R) products increased by 9% to GBP11.1 million (2017 H1: GBP10.2 million), and by 6% at constant currency.
Within this, sales of sutures increased by 7% to GBP6.8 million (2017 H1: GBP6.4 million) and by 4% at constant currency and sales of bio-surgical products increased by 18% to GBP4.3 million (2017 H1: GBP3.7 million) and by 14% at constant currency.
Of the GBP11.1 million sales, GBP6.6 million (2017 H1: GBP6.5 million) were in Germany, up 2% on the prior year but down 1% at constant currency, while sales outside Germany increased by 20% to GBP4.5 million (2017 H1: GBP3.8 million) and 17% at constant currency. We continue to access new markets, in particular Asia Pacific, and target specific applications for our RESORBA(R) brands.
In R&D, we are continuing to work on the development and approval of ranges of collagens incorporating a variety of different antibiotics, including an application in cardiac surgery.
ActivHeal(R)
ActivHeal(R) is our range of high-quality and cost-effective woundcare dressings sold predominately to the NHS.
Sales of ActivHeal(R) increased by 6% to GBP3.4 million (2017 H1: GBP3.2 million) in the period. The raw material issue, previously reported, was resolved at the end of last year and our new antimicrobial, atraumatic foam and high-performance products have been added to the range.
OEM Business unit
Our sales in the period were impacted by weakness in the woundcare market, which we reported in 2017, ordering patterns of our partners, and the decision of Hollister, one of our US partners, to exit the market. As a result, revenue decreased 6% to GBP17.6 million (2017 H1: GBP18.7 million(6) ) and by 4% at constant currency.
-- Sales of antimicrobial dressings decreased by 15% to GBP8.2 million (2017 H1: GBP9.7 million) and by 13% at constant currency
-- Sales of non-antimicrobial foam dressings increased by 6% at reported currency to GBP3.6 million (2017 H1: GBP3.4 million) and by 5% at constant currency
-- Sales of other technologies, including alginates, gels and royalties, increased by 3% to GBP5.8 million (2017 H1: GBP5.6 million) and by 7% at constant currency. This included GBP0.7 million relating to royalty income from Organogenesis, on sales of PHMB collagen (2017 H1: GBPnil)
We have multiple opportunities underway to drive future growth through market expansion and from extending our anti-microbial product ranges.
In June 2018, we received European approval for our atraumatic Lite foam which is an extension to our silicone foam portfolio. It is intended for managing wounds with low levels of exudate such as minor burns, leg and foot ulcers and post-operative surgical wounds towards the end of the healing process. The dressing has a soft silicone 'atraumatic' adhesive which can be repositioned during wear. With the Non-Border variant having been CE-Marked in November 2017, and the addition of some new post-operative sizes enabling us to compete in the surgical market we now have the full complement of variants for this product range.
In August 2018, we received pre-market approval from the FDA in the US to market our Surgical Silver Post-Operative dressings and PHMB foam dressings. It is expected that both ranges will be launched into the US around the end of 2018.
The Surgical Silver Post-Operative dressing consists of two skin-friendly layers of hydrocolloid securing a silver-containing absorbent antibacterial alginate dressing and has been shown to be effective against Methicillin-Resistant S. aureus (MRSA) as well as a broad spectrum of microbes including other antibiotic resistant strains.
Our PHMB Foam Dressing is a polyurethane foam impregnated with polyhexamethylene biguanide that can be used in managing various chronic and post-surgical wounds including, diabetic ulcers and burns and has strong antimicrobial and fluid handling performance. This range was launched in Europe in 2016 following EU approval, whilst launches to our US partners were deferred pending approval for the extended claims.
We have recently received approval from ANVISA, the Regulatory Body in Brazil, to market a range of advanced woundcare products into Brazil and have identified a partner to work with, that expects to launch at the end of this year. This will be our first OEM partner in Latin America. We have also added a new partner for the US that has agreed a four-year contract for a range of advanced woundcare products and also expects to launch in the fourth quarter.
In R&D we continue to extend our product portfolio with atraumatic PHMB foam and silver high performance dressings anticipated to launch in the next two years.
Operations and regulatory
To meet market demand and continue our sustained organic growth, we continue to make investments in our facilities and equipment. In the first six months of the year, we have invested in improved packaging capability at Nuremberg and in initial planning work related to extending the capacity of the Plymouth site.
The new European Medical Devices Regulation (MDR) entered into force on 25 May 2017, marking the start of the transition period for manufacturers selling medical devices into Europe. The MDR, which replaces the Medical Devices Directive (MDD) has a transition period of three years and manufacturers have this transition period to update their technical documentation and processes to meet the new requirements. The MDR brings more scrutiny on product safety and performance and stricter requirements on clinical evaluation and post-market clinical follow up.
There will be fewer Notified Bodies approved to certify medical devices under MDR and they are indicating resource constraints within their organisations as they strive to meet the new regulatory requirements. The backlog is being further compounded as medical device companies losing their Notified Body have to transfer to one of those remaining. For all Medical Device companies, there will be significant, additional work and costs associated with meeting the new requirements. Short term there may be delays in getting products approved and recertified. In the longer term, once the transition is completed, the tighter regulatory standards should prove beneficial for the Group and will provide a significant barrier to market entry. The five year product recertification process for RESORBA(R) is currently in progress and is consequently proving to be onerous.
In the UK the Group's Notified Body is BSI. Following the triggering of Article 50, BSI expects to remain a full member and influential participant in the single European Standards system as well as an EU Notified Body.
If no withdrawal agreement is achieved with Europe, BSI anticipates that a mutual recognition agreement for UK Notified Bodies will be agreed. Currently there are recognised existing mechanisms in place for non-EU countries to participate as EU Notified Bodies. For example, the designated organisations in Norway (under EEA recognition), Switzerland and Australia (through Mutual Recognition Agreements) are recognised as Notified Bodies for the purposes of the relevant EU legislation.
We further understand that BSI is strengthening its European links to secure BSI's EU Notified Body activity in mainland Europe. BSI has formally applied for designation as a Medical Device Notified Body in the Netherlands and is working through the process of designation. In a worst case scenario, companies would be able to transfer to BSI Netherlands from BSI UK.
Referendum vote to leave the EU
The Group is well placed to deal with the uncertain outcome of the Brexit negotiations. The Group already has a strong footprint in mainland Europe and in March 2018, the UK trading entity was granted Authorised Economic Operator (AEO) status by HMRC. In the event, of "no deal", the World Trade Organisation (WTO) tariff rates for our finished goods are currently favourable and on the back of our AEO status, we are in a good position to secure reliefs against import duties on our raw material imports.
Acquisitions strategy
We have an internal team actively working with advisors to identify, appraise and progress targets that meet our strategy of:
-- licensing or acquiring technology that allows us to leverage our global routes to market -- licensing or acquiring complementary surgical or woundcare brands
-- geographic expansion through acquiring surgically focused companies with strong direct sales capability and ownership of complementary products
The Group is actively monitoring and evaluating acquisition opportunities to capitalise on its strong financial and strategic position.
Summary and outlook
The first half of 2018 has seen another good performance by the Group and we are confident of meeting Board expectations for the full year. With our new product launches, strong partners and the opportunities we see from our R&D pipeline, the Board remains optimistic about our long-term prospects and the potential for further organic growth, as well as by means of acquisitions.
Financial Review
Overview
Revenue increased by 3.2% to GBP47.6 million (2017 H1: GBP46.1 million(6) ). At constant currency, revenue growth would have been 5.6%.
Amortisation of acquired intangible assets was less than GBP0.1 million in the six month period (2017 H1: GBP0.1 million).
Comparisons with 2017 are made on a pre-exceptional and pre-amortisation of acquired intangible asset cost basis, as we believe that this provides a more relevant representation of the Group's trading performance. To aid comparison, the Group's adjusted income statement is summarised in Table 1 below.
Table 1 Six months Six months ended
ended 30 June 2017
30 June 2018
Adjusted Income Statement GBP'000 GBP'000 (restated(6) Change
)
--------------------------------- -------------- -------------------------- -------
Revenue(6) 47,621 46,126 3.2%
--------------------------------- -------------- -------------------------- -------
Gross profit 29,995 27,694 8.3%
Distribution costs (614) (534) 15.0%
Adjusted administrative
expenses(7) (15,864) (15,711) 1.0%
Other income 59 57 3.5%
--------------------------------- -------------- -------------------------- -------
Adjusted operating profit 13,576 11,506 18.0%
Net finance income 98 -
--------------------------------- -------------- -------------------------- -------
Adjusted profit before
tax(5) 13,674 11,506 18.8%
Amortisation of acquired
intangibles (40) (94)
Profit before tax 13,634 11,412 19.5%
Tax (2,866) (2,301) 24.6%
--------------------------------- -------------- -------------------------- -------
Profit for the period 10,768 9,111 18.2%
--------------------------------- -------------- -------------------------- -------
Adjusted earnings per share
- basic(8) 5.08p 4.37p 16.2%
Earnings per share - basic(8) 5.06p 4.32p 17.1%
--------------------------------- -------------- -------------------------- -------
Adjusted earnings per share
- diluted(8) 5.01p 4.31p 16.2%
Earnings per share - diluted(8) 4.99p 4.26p 17.1%
--------------------------------- -------------- -------------------------- -------
7 Administration expenses exclude amortisation of acquired intangible assets
8 see Note 4 Earnings per share for details of calculation
The gross margin percentage for the Group was 63.0% (2017 H1: 60.0%). This 300 bps increase in gross margin was mainly as a result of sales mix and the out-licensing agreement with Organogenesis for wound dressings containing collagen and PHMB, which generated GBP0.7 million royalty income in the period.
Adjusted operating profit increased by 18.0% to GBP13.6 million (2017 H1: GBP11.5 million) and the adjusted operating margin increased by 360 bps to 28.5% (2017 H1: 24.9%) due to sales mix and the impact of additional royalty income in the period. Administration expenses (excluding amortisation of acquired intangible assets) increased by 1%. Within this, gains from the foreign exchange effects helped to offset a further increase in investment in sales and marketing and increased costs from regulatory and clinical work.
Adjusted diluted earnings per share increased by 16.2% to 5.01p (2017 H1: 4.31p) and diluted earnings per share increased by 17.1% to 4.99p (2017 H1: 4.26p).
The Group generated profit before tax of GBP13.6 million (2017 H1: GBP11.4 million) and had net cash of GBP71.1 million at the half year end (2017 H1: GBP55.2 million).
The Group has a strong balance sheet enabling financing of further organic growth and acquisitions.
Income Statement
The operational performance of the business units is shown in Table 2 below. The adjusted profit from operations and the adjusted operating margin are shown after excluding exceptional items and amortisation of acquired intangibles.
Table 2
Operating result by business
segment
Six months ended 30 June 2018
Branded OEM
GBP'000 GBP'000
--------------------------------------- -------- --------
Revenue 30,060 17,561
Profit from operations 9,903 3,914
Amortisation of acquired intangibles 40 -
Adjusted profit from operations(9) 9,943 3,914
Adjusted operating margin(9) 33.1% 22.3%
--------------------------------------- -------- --------
Six months ended 30 June 2017
represented
Revenue(6) (restated) 27,440 18,686
Profit from operations 7,936 3,724
Amortisation of acquired intangibles 89 5
Adjusted profit from operations(9) 8,025 3,729
Adjusted operating margin(9) 29.2% 20.0%
--------------------------------------- -------- --------
9 Excludes amortisation of acquired intangible assets which, in 2018 H1, were less than GBP0.1 million (2017 H1: GBP0.1 million)
Expenses relating to exceptional items, to non-executive Directors and plc costs are not allocated to business units and are included within unallocated expenses.
Branded
Branded revenues increased by 9.5% to GBP30.1 million (2017 H1: GBP27.4 million(6) ) and by 11.9% at constant currency, with sales of LiquiBand(R) into the US being the main driver of growth.
Adjusted operating margin increased by 390 bps to 33.1% (2017 H1: 29.2%) despite ongoing investment in our sales & marketing teams. R&D expense was 2.5% of revenues (2017 H1: 2.1%) with expenditure in this segment being incurred on projects to improve our formulation and applicators for tissue adhesives, as well as ongoing development of the internal use of tissue adhesives.
OEM
OEM revenues decreased by 6.0% to GBP17.6 million (2017 H1: GBP18.7 million(6) ) at reported currency and by 3.7% at constant currency. R&D expense was 5.2% of revenues (2017 H1: 4.1%) with spend being incurred in the development of post-surgical dressings and high performance dressings.
Adjusted operating margin increased by 230 bps to 22.3% (2017 H1: 20.0%).
Geographic breakdown of revenues
The geographic breakdown of Group revenues in 2018 is set out in note 5. Sterling sales represent the largest currency with significant sales also in Euros and US dollars. The Group's policy is to put in place natural hedges where possible and to hedge transactional risk. The Group estimates that a 10% movement in the GBP:US$ or GBP:Euro exchange rate would impact Sterling revenues by approximately 5% and 3% respectively and, in the absence of any hedging, this would result in an impact on profit of 3.6% and 0.8% respectively.
Net finance costs/income
Net finance costs/income is comprised of finance income of GBP157,000 (2017 H1: GBP50,000) representing interest received on cash balances and finance costs of GBP59,000 (2017 H1: GBP51,000) resulting from facility costs.
Profit before tax
Profit before tax for the six months was 19.5% higher at GBP13.6 million (2017 H1: GBP11.4 million).
Taxation
The Group's effective rate of current tax for the six months was 21.0% (2017 H1: 20.2%). This reflects the blend of profits and tax rates in the countries in which the Group operates and incorporates UK patent box and R&D relief. The Group expects its anticipated effective tax rate to be approaching 21% for the full year ending 31 December 2018.
Profit after tax and earnings per share
Adjusted profit after tax increased by 17.4% to GBP10.8 million (2017 H1: GBP9.2 million), resulting in a 16.2% increase in adjusted basic earnings per share to 5.08p (2017 H1: 4.37p) and a 16.2% increase in adjusted diluted earnings per share to 5.01p (2017 H1: 4.31p).
Profit after tax increased 18.2% to GBP10.8 million (2017 H1: GBP9.1 million), resulting in a 17.1% increase in basic earnings per share to 5.06p (2017 H1: 4.32p) and a 17.1% increase in diluted earnings per share to 4.99p (2017 H1: 4.26p).
Dividend per share
The Board intends to pay an interim dividend of 0.42p per share on 26 October 2018 to shareholders on the register on 28 September 2018. This is an increase of 20% compared with the first half of 2017.
Cash Flow and Balance Sheet
Table 3 summarises the Group cash flows.
Table 3 Six months
ended Six months ended
30 June 2018 30 June 2017
Cash Flow GBP'000 GBP'000
------------------------------------------ --------------- -------------------
Adjusted operating profit (Table
1) 13,576 11,506
Non-cash items 2,359 1,970
Adjusted EBITDA(10) 15,935 13,476
Working capital movement (2,212) (4,416)
Operating cash flow 13,723 9,060
Capital expenditure and capitalised
R&D (2,302) (2,236)
Net interest income 98 -
Tax (1,650) (2,048)
Free cash flow 9,869 4,776
Dividends paid (1,591) (1,307)
Proceeds from share issues 381 555
Exchange gains 16 11
Net increase in cash and cash
equivalents 8,675 4,035
------------------------------------------ -------------- -----------------
10 Adjusted EBITDA is earnings before interest, tax, depreciation, intangible asset amortisation, share based payments and exceptional items
The Group had an operating cash flow before exceptional items of GBP13.7 million (2017 H1: GBP9.1 million) and a conversion of adjusted operating profit into free cash flow of 73% (2017 H1: 42%). The increase in cash conversion was due to reduced trade debtors and decreased tax payments, resulting from the recovery of overpayments of tax from previous periods.
Working capital increased by GBP2.2 million. Within this, trade receivables decreased by GBP1.7 million due to timing of sales with debtor days at 43 (2017 H1: 53 days). Inventory increased by GBP2.2 million in the first six months with months of supply being 4.1 (2017 H1: 4.1 months). Trade payables decreased GBP1.7 million.
We have invested GBP2.3 million in fixed assets, software and capitalised R&D in the first six months (2017 H1: GBP2.2 million), including investment in our Nuremberg facility, investigation into potential expansion of our Plymouth facility, new packing machines and microwave dryer machines to enhance our foam manufacturing capabilities. GBP0.5 million of R&D spend was capitalised in the period (2017 H1: GBP0.4 million).
Net taxation of GBP1.7 million was paid which is in line with the Group's profitability within the tax jurisdictions in which it operates.
The Group paid its final dividend for the year ended 31 December 2017 of GBP1.6 million on 15 June 2018 (2017 H1: GBP1.3 million).
The Group had a free cash flow as defined in Table 3 of GBP9.9 million in the period (2017 H1: GBP4.8 million), with a net increase in cash and cash equivalents of GBP8.7 million (2017 H1: GBP4.0 million increase).
At the end of the period, the Group had net cash(11) of GBP71.1 million (2017 H1: net cash(11) of GBP55.2 million).
The Group has a five-year, GBP30 million, multi-currency, revolving credit facility, obtained in December 2014, with an accordion option under which AMS can request up to an additional GBP20 million on the same terms. The facility is provided jointly by HSBC and The Royal Bank of Scotland PLC. It is unsecured on the assets of the Group and is currently wholly undrawn.
The movement in net cash during the first half of 2018 is reconciled in Table 4 below:
Table 4 Movement in net cash(11) GBP'000 ----------------------------- -------------- Net cash as at 1 January 2018 62,454 Exchange rate impacts 16 Free cash flow 9,869 Dividends paid (1,591) Proceeds from share issues 381 Net cash as at 30 June 2018 71,129 ----------------------------- --------------
11 Net cash is defined as cash and cash equivalents plus short term investments less financial liabilities and bank loans
The Group's going concern position is fully described in note 11 and the Group had no borrowings in the period.
CONDENSED CONSOLIDATED INCOME STATEMENT for the six months ended 30 June 2018
(Unaudited) (Unaudited) (Audited)
Six months ended 30 Six months ended 30 Year ended 31 December
June 2018 June 2017 2017
Total Total Total
(restated)
Note GBP'000 GBP'000 GBP'000
------------------------------ ----- -------------------- -------------------- -----------------------
Revenue from continuing
operations(6) 5 47,621 46,126 96,908
Cost of sales (17,626) (18,432) (38,504)
------------------------------ ----- -------------------- -------------------- -----------------------
Gross profit 29,995 27,694 58,404
Distribution costs (614) (534) (1,130)
Administration costs (15,904) (15,804) (32,184)
Other income 59 57 150
Profit from operations 13,536 11,413 25,240
Finance income 157 50 147
Finance costs (59) (51) (110)
------------------------------ ----- -------------------- -------------------- -----------------------
Profit before taxation 13,634 11,412 25,277
Income tax 7 (2,866) (2,301) (5,143)
------------------------------ ----- -------------------- -------------------- -----------------------
Profit for the period
attributable
to equity holders of the
parent 10,768 9,111 20,134
------------------------------ ----- -------------------- -------------------- -----------------------
Earnings per share
Basic 4 5.06p 4.32p 9.52p
Diluted 4 4.99p 4.26p 9.39p
Adjusted(12) diluted 4 5.01p 4.31p 9.46p
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited) (Unaudited) (Audited)
Six months ended 30 Six months ended 30 Year ended 31 December
June 2018 June 2017 2017
GBP'000 GBP'000 GBP'000
------------------------------------ -------------------- -------------------- -----------------------
Profit for the period 10,768 9,111 20,134
Items that will potentially
be reclassified subsequently
to profit and loss
Exchange differences on translation
of foreign operations (4) 1,548 2,187
(Loss)/gain arising on cash
flow hedges (1,613) 2,556 4,192
------------------------------------- -------------------- -------------------- -----------------------
Other comprehensive (expense)/income
for the period (1,617) 4,104 6,379
------------------------------------- -------------------- -------------------- ----------------------- Total comprehensive income for the period attributable to equity holders of the parent 9,151 13,215 26,513 ------------------------------------- -------------------- -------------------- -----------------------
(12) Adjusted for exceptional items and for amortisation of acquired intangible assets
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(Unaudited) (Unaudited) (Audited)
30 June 2018 30 June 2017 31 December
2017
GBP'000 GBP'000 GBP'000
Assets
Non-current assets
Acquired intellectual property
rights 9,622 9,629 9,675
Software intangibles 2,876 2,730 3,078
Development costs 2,506 1,747 2,135
Goodwill 41,746 41,430 41,801
Property, plant and equipment 17,683 16,951 17,019
Deferred tax assets 199 - 199
Trade and other receivables 19 13 286
-------------------------------- ------------- ------------- ------------
74,651 72,500 74,193
Current assets
Inventories 13,232 11,182 11,073
Trade and other receivables 18,830 16,712 20,950
Current tax assets - 461 48
Cash and cash equivalents 71,129 55,160 62,454
-------------------------------- ------------- ------------- ------------
103,191 83,515 94,525
-------------------------------- ------------- ------------- ------------
Total assets 177,842 156,015 168,718
-------------------------------- ------------- ------------- ------------
Liabilities
Current liabilities
Trade and other payables 8,856 11,461 10,547
Current tax liabilities 3,310 2,356 2,290
Other taxes payable - 103 15
12,166 13,920 12,852
Non-current liabilities
Trade and other payables 1,262 341 310
Deferred tax liabilities 3,126 2,748 3,120
4,388 3,089 3,430
-------------------------------- ------------- ------------- ------------
Total liabilities 16,554 17,009 16,282
-------------------------------- ------------- ------------- ------------
Net assets 161,288 139,006 152,436
-------------------------------- ------------- ------------- ------------
Equity
Share capital 10,672 10,606 10,632
Share premium 35,148 34,478 34,778
Share-based payments reserve 5,562 4,082 4,676
Investment in own shares (156) (152) (152)
Share-based payments deferred
tax reserve 815 861 815
Other reserve 1,531 1,531 1,531
Hedging reserve (955) (978) 658
Translation reserve 2,819 2,184 2,823
Retained earnings 105,852 86,394 96,675
-------------------------------- ------------- ------------- ------------
Equity attributable to equity
holders of the parent 161,288 139,006 152,436
-------------------------------- ------------- ------------- ------------
CONDENSED CONSOLIDATED Statement of Changes in Equity
Attributable to equity holders of the Group
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
capital premium payments shares deferred reserve reserve reserve earnings Total
tax
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2018
(audited) 10,632 34,778 4,676 (152) 815 1,531 658 2,823 96,675 152,436
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit
for the
period to
30 June 2018 - - - - - - - - 10,768 10,768
Other
comprehensive
income - - - - - - (1,613) (4) - (1,617)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - (1,613) (4) 10,768 9,151
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 907 - - - - - - 907
Share options
exercised 40 370 (21) - - - - - - 389
Shares
purchased by
EBT - - - (600) - - - - - (600)
Shares sold by
EBT - - - 596 - - - - - 596
Dividends paid - - - - - - - - (1,591) (1,591)
At 30 June
2018
(unaudited) 10,672 35,148 5,562 (156) 815 1,531 (955) 2,819 105,852 161,288
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
capital premium payments shares deferred reserve reserve reserve earnings Total
tax
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2017
(audited) 10,524 34,005 3,469 (152) 459 1,531 (3,534) 636 78,590 125,528
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit
for the
period to
30 June 2017 - - - - - - - - 9,111 9,111
Other
comprehensive
income - - - - - - 2,556 1,548 - 4,104
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - 2,556 1,548 9,111 13,215
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 613 - 402 - - - - 1,015
Share options
exercised 82 473 - - - - - - - 555
Shares
purchased by
EBT - - - (484) - - - - - (484)
Shares sold by
EBT - - - 484 - - - - - 484
Dividends paid - - - - - - - - (1,307) (1,307)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 30 June
2017
(unaudited) 10,606 34,478 4,082 (152) 861 1,531 (978) 2,184 86,394 139,006
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
capital premium payments shares deferred reserve reserve reserve earnings Total
tax
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2017
(audited) 10,524 34,005 3,469 (152) 459 1,531 (3,534) 636 78,590 125,528
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit
for the year
to 31
December 2017 - - - - - - - - 20,134 20,134
Other
comprehensive
income - - - - - - 4,192 2,187 - 6,379
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - 4,192 2,187 20,134 26,513
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 1,279 - 356 - - - - 1,635
Share options
exercised 108 773 (72) - - - - - - 809
Shares
purchased by
EBT - - - (484) - - - - - (484)
Shares sold by
EBT - - - 484 - - - - - 484
Dividends paid - - - - - - - - (2,049) (2,049)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 31 December
2017
(audited) 10,632 34,778 4,676 (152) 815 1,531 658 2,823 96,675 152,436
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited) (Unaudited) (Audited)
Six months Six months
ended ended Year ended
30 June 30 June 31 December
2018 2017 2017
GBP'000 GBP'000 GBP'000
---------------------------------------------- ------------ ------------ ------------
Cash flows from operating activities
Profit from operations 13,536 11,412 25,240
Adjustments for:
Depreciation 1,080 1,012 2,053
Amortisation - intellectual property
rights 40 94 134
- development costs 128 208 380
- software intangibles 244 137 415
(Increase)/decrease in inventories (2,174) 362 505
Decrease/(increase) in trade
and other receivables 1,714 (4,205) (8,627)
(Decrease)/increase in trade
and other payables (1,752) (573) 73
Share-based payments expense 907 613 1,279
Taxation (1,650) (2,048) (4,486)
Net cash inflow from operating
activities 12,073 7,012 16,966
---------------------------------------------- ------------ ------------ ------------
Cash flows from investing activities
Purchase of software (58) (622) (958)
Capitalised research and development (498) (371) (860)
Purchases of property, plant
and equipment (1,752) (1,278) (2,901)
Disposal of property, plant and
equipment 6 35 264
Interest received 157 50 147
Net cash used in investing activities (2,145) (2,186) (4,308)
---------------------------------------------- ------------ ------------ ------------
Cash flows from financing activities
Dividends paid (1,591) (1,307) (2,049)
Issue of equity shares 385 555 809
Shares purchased by EBT (600) (484) (484)
Shares sold by EBT 596 484 484
Interest paid (59) (50) (110)
Net cash used in financing activities (1,269) (802) (1,350)
---------------------------------------------- ------------ ------------ ------------
Net increase in cash and cash
equivalents 8,659 4,024 11,308
Cash and cash equivalents at
the beginning of the period 62,454 51,125 51,125
Effect of foreign exchange rate
changes 16 11 21
Cash and cash equivalents at
the end of the period 71,129 55,160 62,454
---------------------------------------------- ------------ ------------ ------------
Notes Forming Part of the Consolidated Financial Statements
1. Reporting entity
Advanced Medical Solutions Group plc ("the Company") is a public limited company incorporated and domiciled in England and Wales (registration number 2867684). The Company's registered address is Premier Park, 33 Road One, Winsford Industrial Estate, Cheshire, CW7 3RT.
The Company's ordinary shares are traded on the AIM market of the London Stock Exchange plc. The consolidated financial statements of the Company for the twelve months ended 31 December 2017 comprise the Company and its subsidiaries (together referred to as the "Group").
The Group is primarily involved in the design, development and manufacture of surgical and advanced woundcare products for sale into the global medical device market.
2. Basis of preparation
The information for the year ended 31 December 2017 does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor reported on those accounts; their report was unqualified, did not draw attention to any matters of emphasis without qualifying the report and did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.
The individual financial statements for each Group company are presented in the currency of the primary economic environment in which it operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each Group company are expressed in pounds sterling, which is the functional currency of the Company and the presentation currency for the consolidated financial statements.
3. Accounting policies
The same accounting policies, presentations and methods of computation are followed in the condensed set of financial statements as applied in the Group's latest annual audited financial statements. No new or revised standards adopted in the current period have had a material impact on the Group's financial statements, including IFRS9 financial instruments. IFRS15 Revenue arising from contracts with customers was adopted in 2017.
The Group will adopt IFRS 16 'Leases' on 1 January 2019. IFRS 16 provides a single model for leases which recognises a right of use asset and lease liability for all leases which are longer than one year or which are not classified as low value. The most significant impact will be that the Group's land, buildings and car leases will be recognised on the balance sheet. The Group has completed initial impact assessments and anticipates adopting the modified retrospective approach permitted under IFRS 16 with no restatement of comparative information.
The unaudited condensed set of financial statements included in this half-yearly financial report have been prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting', as adopted by the European Union. These condensed interim accounts should be read in conjunction with the annual accounts of the Group for the year ended 31 December 2017. The annual financial statements of Advanced Medical Solutions Group plc are prepared in accordance with International Financial Reporting Standards as adopted by the European Union.
4. Earnings per share
(Unaudited) (Unaudited) (Audited)
Six months Six months Year
ended ended ended
30 June 30 June 31 December
2018 2017 2017
GBP'000 GBP'000 GBP'000
----------------------------------- ------------ ------------ ------------
Earnings
Earnings for the purposes
of basic and diluted earnings
per share being net profit
attributable to equity holders
of the parent 10,768 9,111 20,134
Number of shares '000 '000 '000
----------------------------------- ------------ ------------ ------------
Weighted average number of
ordinary shares for the purposes
of basic earnings per share 212,836 210,838 211,563
----------------------------------- ------------ ------------ ------------
Effect of dilutive potential
ordinary shares: share options,
deferred share bonus, LTIPs 3,057 2,942 2,760
----------------------------------- ------------ ------------ ------------
Weighted average number of
ordinary shares for the purposes
of diluted earnings per share 215,893 213,780 214,323
----------------------------------- ------------ ------------ ------------
Basic EPS is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of shares outstanding during the period.
Diluted EPS is calculated on the same basis as basic EPS but with the further adjustment to the weighted average shares in issue to reflect the effect of all potentially dilutive share options. The number of potentially dilutive share options is derived from the number of share options and awards granted to employees where the exercise price is less than the average market price of the Company's ordinary shares during the period.
4. Earnings per share continued
Adjusted earnings per share
Adjusted EPS is calculated after adding back exceptional items and amortisation of acquired intangible assets and is based on earnings of:
(Unaudited) (Unaudited) (Audited)
Six months Six months Year
Ended ended ended
30 June 30 June 31 December
2018 2017 2017
GBP'000 GBP'000 GBP'000
------------------------------------- ------------ ------------ ------------
Earnings
Earnings for the purposes
of basic and diluted earnings
per share being net profit
attributable to equity holders
of the parent 10,768 9,111 20,134
Amortisation of acquired intangible
assets 40 94 134
Earnings excluding exceptional
items and amortisation of
acquired intangible assets 10,808 9,205 20,268
------------------------------------- ------------ ------------ ------------
The denominators used are the same as those detailed above for both basic and diluted earnings per share.
(Unaudited) (Unaudited) (Audited)
Six months Six months Year
Ended ended ended
30 June 30 June 31 December
2018 2017 2017
pence pence pence
---------------------- ------------ ------------ ------------
Adjusted basic EPS 5.08p 4.37p 9.58p
Adjusted diluted EPS 5.01p 4.31p 9.46p
---------------------- ------------ ------------ ------------
The adjusted diluted EPS information is considered to provide a fairer representation of the Group's trading performance.
5. Segment information
Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly investments and related revenue, corporate assets, head office expenses, exceptional items, income tax assets and the Group's external borrowings. These are the measures reported to the Group's Chief Executive for the purposes of resource allocation and assessment of segment performance.
Business segments
The principal activities of the business units are as follows.
Branded
Selling, marketing and innovation of the Group's branded products either sold directly by our sales teams or by distributors.
OEM
Distribution, marketing and innovation of the Group's products supplied to medical device partners under their brands and the distribution of bulk materials to medical device partners and convertors.
Segment information about these Business Units is presented below:
Six months ended
30 June 2018 Branded OEM Consolidated
(unaudited) GBP'000 GBP'000 GBP'000
------------------------ -------- -------- -------------
Revenue 30,060 17,561 47,621
------------------------ -------- -------- -------------
Result
------------------------ -------- -------- -------------
Segment result 9,903 3,914 13,817
Unallocated expenses (281)
-------------
Profit from operations 13,536
Finance income 157
Finance costs (59)
------------------------ -------- -------- -------------
Profit before tax 13,634
Tax (2,866)
------------------------ -------- -------- -------------
Profit for the period 10,768
------------------------ -------- -------- -------------
5. Segment information (continued)
At 30 June 2018
(unaudited) Branded OEM Consolidated
Other information GBP'000 GBP'000 GBP'000
-------------------------------- -------- -------- -------------
Capital additions:
Software intangibles 20 38 58
Development 279 219 498
Property, plant and equipment 1,319 433 1,752
Depreciation and amortisation (653) (839) (1,492)
-------------------------------- -------- -------- -------------
Balance sheet
Assets
Segment assets 122,852 54,929 177,781
Unallocated assets 61
-------------------------------- -------- --------
Consolidated total assets 177,842
-------------------------------- -------- -------- -------------
Liabilities
Segment liabilities 10,861 5,693 16,554
-------------------------------- -------- -------- -------------
Consolidated total liabilities 16,554
-------------------------------- -------- -------- -------------
Six months ended
30 June 2017 Branded OEM Consolidated
(unaudited) GBP'000 GBP'000 GBP'000
------------------------ -------- -------- -------------
Revenue(6) (restated) 27,440 18,686 46,126
------------------------ -------- -------- -------------
Result
------------------------ -------- -------- -------------
Segment result 7,936 3,724 11,660
Unallocated expenses (248)
-------------
Profit from operations 11,412
Finance income 50
Finance costs (50)
------------------------ -------- -------- -------------
Profit before tax 11,412
Tax (2,301)
------------------------ -------- -------- -------------
Profit for the period 9,111
------------------------ -------- -------- -------------
At 30 June 2017
(unaudited) Branded OEM Consolidated
Other information GBP'000 GBP'000 GBP'000
-------------------------------- -------- -------- -------------
Capital additions:
Software intangibles 612 10 622
Development 271 100 371
Property, plant and equipment 591 652 1,243
Depreciation and amortisation (664) (787) (1,451)
-------------------------------- -------- -------- -------------
Balance sheet
Assets
Segment assets 113,873 42,039 155,912
Unallocated assets 103
-------------------------------- -------- --------
Consolidated total assets 156,015
-------------------------------- -------- -------- -------------
Liabilities
Segment liabilities 10,153 6,856 17,009
-------------------------------- -------- -------- -------------
Consolidated total liabilities 17,009
-------------------------------- -------- -------- -------------
5. Segment information (continued)
Year ended
31 December 2017 Branded OEM Consolidated
(audited) GBP'000 GBP'000 GBP'000
------------------------------- ---------- ---------------- --------------
Revenue 55,244 41,664 96,908
------------------------------- ---------- ---------------- --------------
Result
------------------------------- ---------- ---------------- --------------
Segment result 14,336 11,354 25,690
Unallocated expenses (450)
--------------
Profit from operations 25,240
Finance income 147
Finance costs (110)
------------------------------- ---------- ---------------- --------------
Profit before tax 25,277
Tax (5,143)
------------------------------- ---------- ---------------- --------------
Profit for the year 20,134
------------------------------- ---------- ---------------- --------------
At 31 December 2017
(audited) Branded OEM Consolidated
Other Information GBP'000 GBP'000 GBP'000
------------------------------- ---------- ---------------- --------------
Capital additions:
Software intangibles 715 243 958
Development 425 435 860
Property, plant and equipment 1,563 1,338 2,901
Depreciation and amortisation (1,192) (1,790) (2,982)
------------------------------- ---------- ---------------- --------------
Balance sheet
Assets 112,057 56,580 168,637
Segment assets
Unallocated assets 81
------------------------------- ---------- ---------------- --------------
Consolidated total assets 168,718
------------------------------- ---------- ---------------- --------------
Liabilities
Segment liabilities 10,406 5,876 16,282
------------------------------- ---------- ---------------- --------------
Geographical segments
The Group operates in the UK, Germany, the Netherlands, the Czech Republic, with a sales office located in Russia and a sales presence in the USA. In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers. Segment assets are based on the geographical location of the assets.
The following table provides an analysis of the Group's sales by geographical market, irrespective of the origin of the goods or services, based upon location of the Group's customers:
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2018 30 June 2017 (restated) (6) 31 December 2017
GBP'000 GBP'000 GBP'000
--------------------------------------------- ----------------- ---------------------------- -----------------
United Kingdom 9,190 7,768 17,266
Germany 9,653 9,951 19,062
Europe excluding United Kingdom and Germany 10,957 11,358 22,939
United States of America 16,060 16,082 35,330
Rest of World 1,761 967 2,311
--------------------------------------------- ----------------- ---------------------------- -----------------
47,621 46,126 96,908
--------------------------------------------- ----------------- ---------------------------- -----------------
5. Segment information (continued)
The following table provides an analysis of the Group's total assets by geographical location.
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2018 30 June 2017 31 December 2017
GBP'000 GBP'000 GBP'000
--------------------------------------------- ----------------- ----------------- -----------------
United Kingdom 107,561 89,352 98,305
Germany 64,604 61,904 65,212
Europe excluding United Kingdom and Germany 5,193 4,197 4,743
United States of America 484 562 458
--------------------------------------------- ----------------- ----------------- -----------------
177,842 156,015 168,718
--------------------------------------------- ----------------- ----------------- -----------------
6. Financial Instruments' fair value disclosures
It is the policy of the Group to enter into forward foreign exchange contracts to cover specific foreign currency payments and receipts.
The Group held the following financial instruments at fair value at 30 June 2018. The Group has no financial instruments with fair values that are determined by reference to significant unobservable inputs i.e. those that would be classified as level 3 in the fair value hierarchy, nor have there been any transfers of assets or liabilities between levels of the fair value hierarchy. There are no non-recurring fair value measurements.
The following table details the forward foreign currency contracts outstanding as at the period end:
Ave. exchange rate Foreign currency Fair value
30 June 2018 31 Dec 2017 30 June 2018 31 Dec 2017 30 June 2018 31 Dec 2017
USD:GBP1 USD:GBP1 USD'000 USD'000 GBP'000 GBP'000
Cash flow hedges
Sell US dollars
Less than 3 months 1.284 1.382 7,500 8,500 163 (132)
3 to 6 months 1.282 1.369 7,300 6,500 187 (39)
7 to 12 months 1.374 1.283 15,900 14,800 (343) 693
Over 12 months 1.443 1.289 20,000 5,900 (955) 277
-------------------- ------------- ------------ ----------------- ------------ ------------- ------------
50,700 35,700 (948) 799
-------------------- ------------- ------------ ----------------- ------------ ------------- ------------
Ave. exchange rate Foreign currency Fair value
30 June 2018 31 Dec 2017 30 June 2018 31 Dec 2017 30 June 2018 31 Dec 2017
EUR:GBP1 EUR:GBP1 EUR'000 EUR'000 GBP'000 GBP'000
Cash flow hedges
Sell Euros
Less than 3 months 1.146 1.215 650 1,000 (8) (66)
3 to 6 months 1.134 1.177 1,150 1,100 (7) (46)
7 to 12 months 1.115 1.138 1,560 1,800 5 (29)
Over 12 months 1.109 - 2,240 - 3 -
-------------------- ------------ ----------------- ------------ ------------- ------------
5,600 3,900 (7) (141)
-------------------- ------------- ------------ ----------------- ------------ ------------- ------------
7. Taxation
The weighted average tax rate for the Group for the six month period ended 30 June 2018 was 20.7% (first half of 2017: 21.4%, year ended 31 December 2017: 21.9%). The Groups effective tax rate for the full year is expected to be 21.0%, which has been applied to the six months ended 30 June 2018 (first half of 2017: 20.2%, year ended 31 December 2017: 20.4%) after the impact of some disallowable expenditure offset to some extent by the application of patent box and research and development tax relief.
8. Dividends
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2018 30 June 2017 31 December 2017
GBP'000 GBP'000 GBP'000
Amounts recognised as distributions to equity holders in the
period:
Final dividend for the year ended 31 December 2016 of 0.62p
per ordinary share - 1,307 1,307
Interim dividend for the year ended 31 December 2017 of
0.35p per ordinary share - - 742
Final dividend for the year ended 31 December 2017 of 0.75p 1,591 - -
per ordinary share
----------------- ----------------- -----------------
1,591 1,307 2,049
9. Contingent liabilities
The Directors are not aware of any contingent liabilities faced by the Group as at 30 June 2018 (30 June 2017: GBPnil, 31 December 2017: GBPnil).
10. Share capital
Share capital as at 30 June 2018 amounted to GBP10,672,000 (30 June 2017: GBP10,606,000, 31 December 2017: GBP10,632,000). During the period the Group issued 1,317,169 shares in respect of exercised share options, LTIPS, Deferred Annual Bonus Scheme and the Deferred Share Bonus Scheme.
11. Going concern
In carrying out their duties in respect of going concern, the Directors have carried out a review of the Group's financial position and cash flow forecasts for the next 12 months. These have been based on a comprehensive review of revenue, expenditure and cash flows, taking into account specific business risks and the current economic environment.
With regards to the Group's financial position, it had cash and cash equivalents at 30 June 2018 of GBP71.1 million and a five-year, GBP30 million, multi-currency, revolving credit facility, obtained in December 2014, with an accordion option under which AMS can request up to an additional GBP20 million on the same terms. The credit facility is provided jointly by HSBC and The Royal Bank of Scotland PLC. It is unsecured on the assets of the Group and is currently undrawn.
While the current economic environment is uncertain, AMS operates in markets whose demographics are favourable, underpinned by an increasing need for products to treat chronic and acute wounds. Consequently, market growth is predicted. The Group has a number of long-term contracts with customers across different geographic regions and also with substantial financial resources, ranging from government agencies through to global healthcare companies.
After taking the above into consideration, the Directors have reached the conclusion that the Group is well placed to manage its business risks in the current economic environment. Accordingly, they continue to adopt the going concern basis in preparing the condensed consolidated financial statements.
12. Principal risks and uncertainties
Further detail concerning the principal risks affecting the business activities of the Group is detailed on pages 32 and 33 of the Annual Report and Accounts for the year ended 31 December 2017. There have been no significant changes since the last annual report.
13. Seasonality of sales
There are no significant factors affecting the seasonality of sales between the first and second half of the year.
14. Events after the balance sheet date
There has been no material event subsequent to the end of the interim reporting period ended 30 June 2018.
15. Copies of the interim results
Copies of the interim results can be obtained from the Group's registered office at Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, CW7 3RT and are available on our website "www.admedsol.com".
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR BFLLFVKFZBBV
(END) Dow Jones Newswires
September 12, 2018 02:01 ET (06:01 GMT)
1 Year Advanced Medical Solutions Chart |
1 Month Advanced Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
